Combination BP meds raise risk of mortality in elderly
Researchers raised concerns about the safety of prescribing combination antihypertensive medications in elderly patients with low blood pressure, in a new JAMA Internal Medicine study.
Researchers raised concerns about the safety of prescribing combination antihypertensive medications in elderly patients with low blood pressure, in a new JAMA Internal Medicinestudy.
Published in the April 7 issue of the journal, the article was authored by Wilbert S. Aronow, MD, with the cardiology division at Westchester Medical Center/New York Medical College in Valhalla, N.Y.
Related: FDA should pull diabetes drug ads
While clinical evidence supports the beneficial effects of lowering blood pressure (BP) levels in community-living, robust, hypertensive individuals aged older than 80 years, observational studies in frail elderly patients have shown no or even an inverse relationship between BP and morbidity and mortality, according to Dr Aronow.
To that end, Dr Aronow conducted a longitudinal study with elderly residents of nursing homes, analyzing the interaction between low systolic blood pressure (SBP) and the presence of combination antihypertensive treatment on two-year, all-cause mortality. A total of 1,127 women and men aged 80 years and older living in nursing homes in France and Italy were monitored for 2 years. Patients with a SBP less than 130 mm Hg who were receiving combination antihypertensive treatment were compared with all other participants.
Related:Non-PCP blood pressure screens lead to more diagnoses, better management
A significant interaction was found between low SBP and treatment with 2 or more BP-lowering agents, resulting in a higher risk of mortality in patients with low SBP who were receiving multiple BP medicines compared with the other participants.
“The findings of this study raise a cautionary note regarding the safety of using combination antihypertensive therapy in frail elderly patients with low SBP (greater than 130 mm Hg),” Aronow wrote. “Dedicated, controlled interventional studies are warranted to assess the corresponding benefit to risk ratio in this growing population.”
The article did not list which antihypertensive medications the patients were taking.
Read next: Despite risks in elderly, benzodiazepine use increases with age
Navitus to Offer Unbranded Stelara Biosimilar, Remove Stelara from Formulary
March 13th 2025Lumicera Health Services, Navitus’ specialty pharmacy, has made a deal with Teva to offer an unbranded biosimilar that they estimate will save $112,000 and $336,000 per patient per year. Navitus will remove Stelara from formulary on July 1, 2025.
Read More
FDA Approves Neffy 1 mg Nasal Spray for Pediatric Patients
March 6th 2025Neffy 1 mg is now approved by the FDA to treat pediatric patients who weigh 33 to 65 lbs. Neffy was first FDA-approved as a 2 mg dose in August 2024 for the emergency treatment of anaphylaxis in children and adults weighing at least 66 lbs.
Read More
